ContraVir Pharmaceuticals (CTRV) Rating Lowered to Hold at Maxim Group

ContraVir Pharmaceuticals (NASDAQ:CTRV) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Separately, ValuEngine upgraded ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.

ContraVir Pharmaceuticals (NASDAQ:CTRV) traded up $0.04 during trading hours on Tuesday, hitting $0.29. The company had a trading volume of 8,392,400 shares, compared to its average volume of 985,309. ContraVir Pharmaceuticals has a fifty-two week low of $0.23 and a fifty-two week high of $1.96. The firm has a market cap of $19.71, a price-to-earnings ratio of -0.59 and a beta of 1.92.

A hedge fund recently raised its stake in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,414,475 shares of the biopharmaceutical company’s stock after purchasing an additional 366,192 shares during the quarter. Vanguard Group Inc. owned 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 6.71% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply